(Unaudited) (Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
---------------- ----------------
(In thousands, except per share
amounts) 2008 2007 2008 2007
------- ------- ------- --------
Revenues:
Product Sales $ 826 $ 791 $ 2,457 $ 2,300
Other Revenues -- 168 5 335
------- ------- ------- --------
Total Revenues 826 959 2,462 2,635
Cost and expenses:
Product costs 447 511 1,261 1,141
Product development expenses 423 294 755 560
Selling, general and administrative
expenses 351 307 772 656
------- ------- ------- --------
Total costs and expenses 1,221 1,112 2,788 2,357
------- ------- ------- --------
Net operating (loss) income (395) (153) (326) 278
Interest and other income 56 70 116 146
------- ------- ------- --------
(Loss) income before income taxes (339) (83) (210) 424
Income tax (benefit) expense (101) (23) (50) 187
------- ------- ------- --------
Net (loss) income $ (238) $ (60) $ (160) $ 237
======= ======= ======= ========
Net (loss) income per common share:
Basic $ (0.08) $ (0.02) $ (0.06) $ 0.08
Diluted $ (0.08) $ (0.02) $ (0.06) $ 0.08
======= ======= ======= ========
Weighted average common shares
outstanding:
Basic 2,893 2,903 2,893 2,900
Diluted 2,893 2,903 2,893 3,066
(Unaudited)
At June 30, At December 31,
(In thousands) 2008 2007
--------------- ---------------
Cash, cash equivalents and short-term
investments $ 5,695 $ 5,412
Total assets 10,302 10,412
Net working capital 6,746 6,710
Stockholders' equity $ 9,951 $ 10,057
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries. Press releases and other
information about the Company are available at http://www.immucell.com.
Contact Information: Contact: Michael F. Brigham President and Chief Executive Officer (207) 878-2770 Ext. 3106